Last €80.48 EUR
Change Today +0.97 / 1.22%
Volume 4.8K
BIO On Other Exchanges
Symbol
Exchange
Xetra
Xetra
OTC US
OTC US
OTC US
As of 3:35 PM 11/20/14 All times are local (Market data is delayed by at least 15 minutes).

biotest ag (BIO) Snapshot

Open
€80.00
Previous Close
€79.51
Day High
€81.78
Day Low
€79.10
52 Week High
07/7/14 - €94.70
52 Week Low
11/20/13 - €67.80
Market Cap
1.1B
Average Volume 10 Days
5.8K
EPS TTM
€2.10
Shares Outstanding
6.6M
EX-Date
05/8/14
P/E TM
38.3x
Dividend
€0.57
Dividend Yield
0.71%
Current Stock Chart for BIOTEST AG (BIO)

Related News

No related news articles were found.

biotest ag (BIO) Related Businessweek News

No Related Businessweek News Found

biotest ag (BIO) Details

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological medicinal products worldwide. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Bivigam for primary immune deficiency; Cytotect for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in newborns; Hepatect CP for hepatitis B re-infection prophylaxis; Intratect for primary immune deficiency and secondary antibody deficiency syndromes, as well as autoimmune diseases; Nabi-HB for prophylaxis of hepatitis B virus infection; Varitect CP for zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. The company also provides Albiomin for volume depletion; Biseko for the deficiency of volume and serum proteins; Cofact for the deficiency of clotting factors; Humanalbumin for volume depletion; and Pentaglobin for the treatment of severe bacterial infections. In addition, its products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) for the treatment of congenital cytomegalovirus infections; Civacir for the treatment of hepatitis C infection; Tregalizumab (BT-061) for the treatment of rheumatoid arthritis and psoriasis; Fibrinogen for the deficiency of fibrinogen; and IgM concentrate for severe bacterial infections. Biotest Aktiengesellschaft has a collaboration agreement with AbbVie for the development of monoclonal antibody BT-061. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany.

2,137 Employees
Last Reported Date: 11/12/14
Founded in 1946

biotest ag (BIO) Top Compensated Officers

Chairman of Management Board and Chief Execut...
Total Annual Compensation: €513.0K
Chief Financial Officer, Head of Finances & C...
Total Annual Compensation: €459.0K
Chief Operating Officer and Member of Executi...
Total Annual Compensation: €353.0K
Compensation as of Fiscal Year 2013.

biotest ag (BIO) Key Developments

Biotest Presents New Preclinical Data on Tregalizumab (BT-061)

Biotest AG announced that data from in vitro studies on tregalizumab. Tregalizumab is an antibody that selectively activates naturally occurring regulatory T cells (Tregs), and is currently in Phase 2b clinical development for the treatment of rheumatoid arthritis (RA). This mode of action is unique and totally different from other treatment modalities currently used in RA. Activating regulatory cells may yield high treatment efficacy with less side effects due to lower over all suppression of the immune system. The presented in vitro studies examined the potential of tregalizumab to activate regulatory T-cells in the presence of high levels of pro-inflammatory cytokines as observed in patients with autoimmune diseases such as RA. Further investigations focused on the influence of methotrexate which is widely used as co-medication in RA in combination with tregalizumab. The experiments show that the in vitro activation of regulatory T-cells by tregalizumab is not inhibited either by MTX or by pro-inflammatory cytokines (IL-1?, IL-6 and TNF-?). The scientific evaluation was done in collaboration with the research group of Dr. Helmut Jonuleit, University of Mainz.

Biotest AG Announces Earnings Results for the First Nine Months of 2014; Provides Earnings Guidance for the Full Year of 2014

Biotest AG announced earnings results for the first nine months of 2014. The Group generated revenue of EUR 409.9 million in the period between January and September 2014. This represents an increase of 11.5 % compared to the same period in the previous year, mainly attributable to the increase in sales in Asia and Asia also entails contains these sales into Middle East and the near east region where they traditionally have a very strong market position. Operating profit (EBIT) decreased compared to the same period in the previous year due to the substantial increase in expenses and amounted to EUR 35.3 million for the first nine months of 2014, 11.5 % below the EUR 39.9 million for the same period in the previous year. The financial loss amounted to EUR 3.0 million compared to EUR 3.9 million same period in the previous year. Earnings before taxes (EBT) came in at EUR 32.3 million for the Biotest Group compared to EUR 36.0 million for the same period in the previous year. Earnings after taxes (EAT) also decreased from EUR 24.0 million to EUR 19.3 million on an increased tax rate. Earnings per share were - also as a result of the increased number of shares by way of the capital increase in the summer of 2013 to EUR 1.46 compared to EUR 1.96 for the first nine months of 2013. The decrease in earnings before interest and tax of 11.5% compared to the same period in 2013 is explainable by the fact that they have invested quite a lot in those ongoing and well-progressing project as Civacir and the development of BT-061 in Phase IIb study. For the full year 2014, the board of management expects for 2014 a sales increase above 7 % and an operating result (EBIT) in the range of the previous year.

Biotest AG Announces Results of Civacir(R) (Hepatitis C Immune Globulin) US Phase III Study Clinical Trial

Biotest AG announced safety interim results from its ongoing US Phase III study (Study 988) with Civacir at the Congress of the American Association of the Study of Liver Disease (AASLD) in Boston, Massachusetts, USA. Biotest Pharmaceuticals Corporation (BPC) is the manufacturer of an investigational Hepatitis C immune globulin (Civacir(R)) worldwide. In the ongoing Phase III trial, Civacir(R) is being investigated in patients who receive a liver transplant due to chronic hepatitis C infection. End-stage liver disease due to hepatitis C infection is a common indication for liver transplantation. However, newly transplanted livers are rapidly infected by hepatitis C viruses which are still circulating in the patient's body. Currently, there is no approved treatment available to prevent recurrence of the hepatitis C virus after transplant surgery since current antiviral regimens are generally not used due to toxicities, tolerability issues and drug-drug interactions minimum within the first 6 months after transplantation. Approximately 30% of liver transplant patients require a second liver transplant within 5 years. This randomized, open-label Phase III trial conducted in 24 clinical centers in the United States is to evaluate the efficacy, safety and pharmacokinetics in the hepatitis C positive transplant population. More than half of the planned patient number has been enrolled in the study. All patients in the study received antiviral treatment prior to transplantation, including new recently approved virostatics. Patients were randomly assigned to the study drug or the control group. Patients who received the study drug received either 200 mg/kg or 300 mg/kg body weight in the peri- and post transplant periods. The control group received no study drug.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO:GR €80.48 EUR +0.97

BIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIO.
View Industry Companies
 

Industry Analysis

BIO

Industry Average

Valuation BIO Industry Range
Price/Earnings 38.5x
Price/Sales 2.0x
Price/Book 2.2x
Price/Cash Flow 19.2x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTEST AG, please visit www.biotest.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.